Beacon Therapeutics
Amy Adelman House is currently the Head of Portfolio Strategy at Beacon Therapeutics. Previously, Amy Adelman held a similar position at AGTC and worked as a Senior Director at a gene therapy company. Amy has a strong background in business development, alliance management, and consulting across various organizations and industries. Amy Adelman holds an MBA from Duke University and a BA from The Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Beacon Therapeutics
2 followers
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness.